HK Stock Market Move | EXTRAWELL PHAR(00858) surged over 45% after Yixin's rise, with expected mid-term profit of around HK$105 million and turning loss into profit year-on-year.
Sino Biopharmaceutical (00858) rose more than 45% after announcing its profit. As of the time of writing, it rose by 45.83%, reaching HKD 0.07, with a turnover of HKD 972,700.
EXTRAWELL PHAR (00858) rose over 45% after profit announcement, reaching 0.07 Hong Kong dollars, with a total turnover of 972,700 Hong Kong dollars as of the time of publication.
On the news front, EXTRAWELL PHAR announced that the group expects to achieve a profit of approximately 100 million Hong Kong dollars to 105 million Hong Kong dollars for the six-month period ending September 30, 2024, compared to a loss for the same period ending September 30, 2023. The expected turnaround from loss to profit in this period is mainly due to non-cash items, resulting from the gain on fair value changes in financial assets recognized in the income statement, while a loss was incurred in the same period in 2023 for the same non-cash item.
Related Articles

MICROPORT NEURO (02172): NuWismen Zhiji Liquid Embolic Agent Enters NMPA Innovation Green Channel

Shenzhen MinDe Electronics Technology (300656.SZ)'s private placement application has passed the review by the Listing Review Center of the Shenzhen Stock Exchange.

QuakeSafe Technologies (300767.SZ)'s application for additional stock issuance has been approved by the Listing Review Center of the Shenzhen Stock Exchange.
MICROPORT NEURO (02172): NuWismen Zhiji Liquid Embolic Agent Enters NMPA Innovation Green Channel

Shenzhen MinDe Electronics Technology (300656.SZ)'s private placement application has passed the review by the Listing Review Center of the Shenzhen Stock Exchange.

QuakeSafe Technologies (300767.SZ)'s application for additional stock issuance has been approved by the Listing Review Center of the Shenzhen Stock Exchange.






